Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17108129)

  • 1. Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel.
    Mohamedali KA; Poblenz AT; Sikes CR; Navone NM; Thorpe PE; Darnay BG; Rosenblum MG
    Cancer Res; 2006 Nov; 66(22):10919-28. PubMed ID: 17108129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel.
    Hsu AR; Cai W; Veeravagu A; Mohamedali KA; Chen K; Kim S; Vogel H; Hou LC; Tse V; Rosenblum MG; Chen X
    J Nucl Med; 2007 Mar; 48(3):445-54. PubMed ID: 17332623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
    Mohamedali KA; Li ZG; Starbuck MW; Wan X; Yang J; Kim S; Zhang W; Rosenblum MG; Navone NM
    Clin Cancer Res; 2011 Apr; 17(8):2328-38. PubMed ID: 21343372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular targeting of ocular neovascularization with a vascular endothelial growth factor121/gelonin chimeric protein.
    Akiyama H; Mohamedali KA; E Silva RL; Kachi S; Shen J; Hatara C; Umeda N; Hackett SF; Aslam S; Krause M; Lai H; Rosenblum MG; Campochiaro PA
    Mol Pharmacol; 2005 Dec; 68(6):1543-50. PubMed ID: 16150930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of biologically active VEGF121 fusion proteins in Escherichia coli.
    Kim S; Mohamedali KA; Cheung LH; Rosenblum MG
    J Biotechnol; 2007 Feb; 128(3):638-47. PubMed ID: 17218033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF.
    Knowles HJ; Athanasou NA
    J Pathol; 2008 May; 215(1):56-66. PubMed ID: 18283716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
    Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
    Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
    Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
    Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VEGF enhancement of osteoclast survival and bone resorption involves VEGF receptor-2 signaling and beta3-integrin.
    Yang Q; McHugh KP; Patntirapong S; Gu X; Wunderlich L; Hauschka PV
    Matrix Biol; 2008 Sep; 27(7):589-99. PubMed ID: 18640270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing VEGF bioactivity with a soluble chimeric VEGF-receptor protein flt(1-3)IgG inhibits testosterone-stimulated prostate growth in castrated mice.
    Lissbrant IF; Hammarsten P; Lissbrant E; Ferrara N; Rudolfsson SH; Bergh A
    Prostate; 2004 Jan; 58(1):57-65. PubMed ID: 14673953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones.
    Guo Y; Wang S; Hoot DR; Clinton SK
    J Nutr Biochem; 2007 Jun; 18(6):408-17. PubMed ID: 17142033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitive angiogenesis imaging of orthotopic bladder tumors in mice using a selective magnetic resonance imaging contrast agent containing VEGF121/rGel.
    Cho EJ; Yang J; Mohamedali KA; Lim EK; Kim EJ; Farhangfar CJ; Suh JS; Haam S; Rosenblum MG; Huh YM
    Invest Radiol; 2011 Jul; 46(7):441-9. PubMed ID: 21512397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models.
    Rosenblum MG; Shawver LK; Marks JW; Brink J; Cheung L; Langton-Webster B
    Clin Cancer Res; 1999 Apr; 5(4):865-74. PubMed ID: 10213223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice.
    Yonou H; Kanomata N; Goya M; Kamijo T; Yokose T; Hasebe T; Nagai K; Hatano T; Ogawa Y; Ochiai A
    Cancer Res; 2003 May; 63(9):2096-102. PubMed ID: 12727825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flt-1, but not Flk-1 mediates hyperpermeability through activation of the PI3-K/Akt pathway.
    Vogel C; Bauer A; Wiesnet M; Preissner KT; Schaper W; Marti HH; Fischer S
    J Cell Physiol; 2007 Jul; 212(1):236-43. PubMed ID: 17311300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors.
    Veenendaal LM; Jin H; Ran S; Cheung L; Navone N; Marks JW; Waltenberger J; Thorpe P; Rosenblum MG
    Proc Natl Acad Sci U S A; 2002 Jun; 99(12):7866-71. PubMed ID: 12060733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.
    Kitagawa Y; Dai J; Zhang J; Keller JM; Nor J; Yao Z; Keller ET
    Cancer Res; 2005 Dec; 65(23):10921-9. PubMed ID: 16322239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoclasts direct bystander killing of cancer cells in vitro.
    Ramnaraine M; Pan W; Clohisy DR
    Bone; 2006 Jan; 38(1):4-12. PubMed ID: 16139579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 111In- or 99mTc-labeled recombinant VEGF bioconjugates: in vitro evaluation of their cytotoxicity on porcine aortic endothelial cells overexpressing Flt-1 receptors.
    Chan C; Cai Z; Su R; Reilly RM
    Nucl Med Biol; 2010 Feb; 37(2):105-15. PubMed ID: 20152709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of vascular endothelial growth factor on RANK gene expression in osteoclast precursors and on osteoclastogenesis.
    Yao S; Liu D; Pan F; Wise GE
    Arch Oral Biol; 2006 Jul; 51(7):596-602. PubMed ID: 16443190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.